Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 14/20 | 0.49 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.38 |
| ▸ | TNKS | O95271 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3839255 | 0.86 | CRHR1 (0.45) | CRHR1F2RL3HSD11B1TNKS | |
| SCHEMBL3364854 | 0.81 | CRHR1 (0.56) | CRHR1F2RL3HSD11B1TNKS | |
| SCHEMBL3364275 | 0.80 | CRHR1 (0.58) | CRHR1F2RL3HSD11B1TNKS | |
| SCHEMBL13618061 | 0.80 | CRHR1 (0.46) | CRHR1F2RL3HSD11B1TNKS | |
| SCHEMBL3839128 | 0.80 | CRHR1 (0.51) | CRHR1HSD11B1 | |
| SCHEMBL368235 | 0.79 | CRHR1 (0.53) | CRHR1F2RL3HSD11B1TNKS | |
| SCHEMBL3367923 | 0.79 | CRHR1 (0.53) | CRHR1F2RL3HSD11B1TNKS | |
| SCHEMBL8297373 | 0.79 | CRHR1 (0.53) | CRHR1F2RL3HSD11B1TNKS | |
| SCHEMBL3399007 | 0.79 | CRHR1 (0.53) | CRHR1F2RL3HSD11B1TNKS | |
| Hydrochloric Acid SCHEMBL3363293 | 0.79 | CRHR1 (0.57) | CRHR1F2RL3HSD11B1TNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2007753-B1 | HETEROCYCLIC GABA ALPHA SUBTYPE SELECTIVE RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2009-11-11 | — | — | EP | disclosed |
| EP-2007753-B1 | HETEROCYCLIC GABA ALPHA SUBTYPE SELECTIVE RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2009-11-11 | — | — | EP | disclosed |
| WO-2007115966-A1 | HETEROCYCLIC GABA ALPHA SUBTYPE SELECTIVE RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-10-18 | — | — | WO | disclosed |
| US-20070238765-A1 | Heterocyclic GABAA subtype selective receptor modulators | ROCHE PALO ALTO LLC | 2007-10-11 | — | — | US | disclosed |
| US-20070238765-A1 | Heterocyclic GABAA subtype selective receptor modulators | ROCHE PALO ALTO LLC | 2007-10-11 | — | — | US | disclosed |
| US-20070238765-A1 | Heterocyclic GABAA subtype selective receptor modulators | ROCHE PALO ALTO LLC | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238765-A1 | Heterocyclic GABAA subtype selective receptor modulators | GABRA1, GABRA2, GABRA3 | CRHR1 96/4885F2RL3 936/4885HSD11B1 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.